Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
EATG at AIDS 2026
1+ day, 16+ hour ago (229+ words) EATG is happy to take part in the 26th International AIDS Conference (AIDS 2026) with four posters and as a co-organiser of the Silver Zone in the Global Village. Whether you are joining in Rio de Janeiro or online, we invite you…...
UNAIDS: "Funding Community-led harm reduction is not optional to end AIDS” - An interview with Anton Basenko
2+ day, 1+ hour ago (231+ words) European AIDS Treatment Group UNAIDS: “Funding Community-led harm reduction is not optional to end AIDS” – An interview with Anton Basenko UNAIDS sat down with Anton Basenko, Executive Director of International Network for People who Use Drugs (INPUD) during the latest…...
Unitaid invests an additional US$15 million to accelerate introduction, adoption and uptake of breakthrough HIV prevention products in diverse regions
2+ day, 4+ hour ago (258+ words) European AIDS Treatment Group Unitaid invests an additional US$15 million to accelerate introduction, adoption and uptake of breakthrough HIV prevention products in diverse regions Building on its broader US$110 million investment in next-generation HIV prevention, Unitaid announced an additional US…...
[Report] Unitaid: Oil price shocks could raise the cost of HIV medicines by up to 44%
2+ day, 4+ hour ago (225+ words) European AIDS Treatment Group [Report] Unitaid: Oil price shocks could raise the cost of HIV medicines by up to 44% Report warns that geopolitical disruptions are exposing a hidden vulnerability in pharmaceutical supply chains, with implications for affordability and health security....
WHO: Consolidated HIV guidelines: service delivery
2+ day, 51+ min ago (194+ words) European AIDS Treatment Group WHO: Consolidated HIV guidelines: service delivery HIV remains a major public health challenge, especially in low- and middle-income countries. Inconsistent or delayed implementation of evidence-based interventions – compounded by workforce shortages, weak supply chains and poor service…...
[Report] amfAR: PEPFAR Pulse Study: Measuring the global impact of PEPFAR disruptions
4+ day, 3+ hour ago (194+ words) European AIDS Treatment Group [Report] amfAR: PEPFAR Pulse Study: Measuring the global impact of PEPFAR disruptions PEPFAR (the U.S. President’s Emergency Plan for AIDS Relief) has been an essential part of the global HIV response by providing funding to prevention, treatment,…...
HIV i-Base: AIDS 2026: Programme highlights to look out for
4+ day, 1+ hour ago (144+ words) Held every two years, the World AIDS Conference organised by the International AIDS Society is the largest international HIV meeting, with good community engagement in a broad programme. In addition to covering basic and clinical science, this conference has a…...
IAS: Data revealing the impact of PEPFAR disruptions and advances in long-acting HIV prevention and treatment announced ahead of AIDS 2026
4+ day, 2+ hour ago (232+ words) European AIDS Treatment Group [AIDS 2026] IAS: Data revealing the impact of PEPFAR disruptions and advances in long-acting HIV prevention and treatment announced ahead of AIDS 2026 21 July 2026 (Rio de Janeiro, Brazil) – Studies revealing the real-world impact of disruptions to the US…...
[AIDS 2026] [Press release] Gilead & Meck: Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who switched antiretroviral therapy
4+ day, 2+ hour ago (366+ words) European AIDS Treatment Group [AIDS 2026] [Press release] Gilead & Merck: Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who switched antiretroviral therapy FOSTER CITY, Calif. & RAHWAY, N.J., July 21, 2026 — Gilead Sciences, Inc. (Nasdaq: GILD)…...
[Advocacy brief] TAG: Overcoming barriers to adopting the four-month regimen: A pathfinding mission to improve access to newer TB treatments
5+ day, 1+ hour ago (250+ words) European AIDS Treatment Group [Advocacy brief] TAG: Overcoming barriers to adopting the four-month regimen: A pathfinding mission to improve access to newer TB treatments Drug-sensitive TB treatment can be shortened from six to four months by replacing rifampicin with rifapentine…...